The Atherogenic Index of Plasma significantly and independently predicted the development of hypertension, diabetes, left ventricular hypertrophy, and cardiovascular events (P<0.0001).
Cohort (n=2,035)
Does the Atherogenic Index of Plasma predict the development of cardiometabolic diseases and cardiovascular events in a general European population?
The Atherogenic Index of Plasma is an independent predictor of incident hypertension, diabetes, left ventricular hypertrophy, and cardiovascular events in a low-risk European population.
p-value: p=<0.0001
INTRODUCTION: The Atherogenic Index of Plasma (AIP), ratio between triglycerides and high-density lipoprotein cholesterol, has been associated with cardiovascular (CV) events, metabolic syndrome and hypertension (HT)-related vascular organ damage. However, the majority of the published studies suffer from important limitations, such as the cross-sectional or retrospective nature and the performance in selected Asian populations only. AIM: We performed a data analysis in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study, examining longitudinally the relationships between AIP, diabetes mellitus (DM), HT and left ventricular hypertrophy (LVH) in a western European general population. METHODS: At the study entry baseline data were collected in 2035 subjects, while longitudinal data were obtained in 1412 subjects examined for a median follow-up time lasting 10.7 years. RESULTS: 50.6% of the subjects were males, aged 50.9 ± 13.7 (mean ± SD) yrs. During the follow-up AIP did not significantly change (from - 0.11 ± 0.3 to - 0.12 ± 0.29 a.u., P = NS), while systolic BP and plasma glucose significantly increased, with a significant relationship with HT, DM and LVH development (P < 0.0001). At multivariable analysis, AIP significantly and independently predicted the above-mentioned outcomes, with the exception of HT development based on home BP. The same significant association was detected for fatal and non-fatal CV events. CONCLUSIONS: These data provide evidence that in a general European population characterized by a low CV risk AIP significantly and independently predicts HT, DM and LVH development and is significantly associated with the composite outcome of CV morbidity and mortality.
Maloberti et al. (Tue,) conducted a cohort in low cardiovascular risk (n=2,035). Atherogenic Index of Plasma (AIP) was evaluated on Development of hypertension, diabetes mellitus, left ventricular hypertrophy, and fatal and non-fatal cardiovascular events (p=<0.0001). The Atherogenic Index of Plasma significantly and independently predicted the development of hypertension, diabetes, left ventricular hypertrophy, and cardiovascular events (P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: